Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743078 · ClinicalTrials.gov registry record · Phase 2
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
A Phase 2 study, sponsored by RTOG Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02743078: Clinical Trial Phase 2 study, sponsored by RTOG Foundation.
NCT02743078 is a Phase 2 study that was terminated before completion, run by RTOG Foundation. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02743078, a Phase 2 study, was terminated before completion, sponsored by RTOG Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields \[TTFields\] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.
Primary Outcome
Number of participants alive at 6 months. Out of the planned 80 eligible patients, if 36 or more were alive at six months then the null hypothesis that the six-month survival rate is 35% or less would be rejected, concluding that the six-month survival is at least 35%. No testing was done due to the small number of participants resulting from early study closure.
Interventions
- DRUG Bevacizumab
- DEVICE TTFields Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-05-09 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
Why NCT02743078 stopped before completion
NCT02743078 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02743078 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02743078 about?
NCT02743078 is a clinical study titled "Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma". This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields \[TTFields\] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.
What is the current status of trial NCT02743078?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-05-09. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT02743078?
The interventions under investigation include: Bevacizumab (DRUG), TTFields Therapy (DEVICE).
Who is sponsoring clinical trial NCT02743078?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02743078's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI